{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:17:29Z","timestamp":1758820649412,"version":"3.37.0"},"reference-count":122,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2009,7,9]],"date-time":"2009-07-09T00:00:00Z","timestamp":1247097600000},"content-version":"unspecified","delay-in-days":7282,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychol. Med."],"published-print":{"date-parts":[[1989,8]]},"abstract":"<jats:title>Synopsis<\/jats:title><jats:p>Evidence is presented here in support of the efficacy of carbamazepine (CBZ) in a variety of different psychiatric conditions. While there is now considerable evidence to support the use of CBZ in the acute treatment of mania and in the prophylaxis of bipolar affective disorder, particularly as a second-line drug, its usefulness in other conditions is less well documented. Overactivity, aggression and poor impulse control appear to improve in a variety of different diagnostic categories, and it may possibly be more appropriately prescribed to control or prevent these symptoms than as a treatment for a particular disease entity. The use of CBZ as an antidepressant is not well proven. Most of the adverse effects reported are due to rapid initial escalation of dosage, which can be avoided, or are reversible such as drug rashes. Severe adverse effects have been reported but are rare. Frequent monitoring of drug plasma concentration is not required. Some reports of synergism with lithium have appeared and combination therapy may be a useful strategy. Drug interactions, the need for clinical monitoring, and the possible pharmacological mode of action of CBZ are also discussed.<\/jats:p>","DOI":"10.1017\/s0033291700024193","type":"journal-article","created":{"date-parts":[[2009,7,9]],"date-time":"2009-07-09T14:28:39Z","timestamp":1247149719000},"page":"591-604","source":"Crossref","is-referenced-by-count":18,"title":["Clinical issues in the use of carbamazepine in psychiatry: a review"],"prefix":"10.1017","volume":"19","author":[{"given":"Martin","family":"Elphick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2009,7,9]]},"reference":[{"key":"S0033291700024193_ref084","first-page":"177","volume-title":"Aspects of Epilepsy and Psychiatry","author":"Post","year":"1986"},{"key":"S0033291700024193_ref120","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1176\/ajp.145.3.339","article-title":"Carbamazepine and hyponatraemia in patients with affective disorders","volume":"145","author":"Yassa","year":"1988","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref014","first-page":"30","article-title":"Lithium and carbamazepine interaction: possible neurotoxicity","volume":"44","author":"Chaudhry","year":"1983","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref119","first-page":"579","article-title":"Chronic lithium, carbamazepine and haloperidol, but not phenytoin stimulate 86Rb uptake by mouse brain P2 fractions","volume":"92","author":"Wood","year":"1987","journal-title":"British Journal of Pharmacology"},{"key":"S0033291700024193_ref117","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0026-895X(25)15168-7","article-title":"Inhibition of binding of [3H]batrachotoxin A 20-\u03b1-benzoate to sodium channels by the anti-convulsant drugs diphenylhydantoin and carbamazepine","volume":"20","author":"Willow","year":"1982","journal-title":"Molecular Pharmacology"},{"key":"S0033291700024193_ref082","first-page":"490","article-title":"The comparative efficacy and safety of carbamazepine versus lithium: a randomised, double-blind three-year trial in 83 patients","volume":"47","author":"Placidi","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref111","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-197701000-00010"},{"key":"S0033291700024193_ref104","first-page":"496","article-title":"Carbamazepine treatment of a patient with Kluver-Bucy syndrome","volume":"46","author":"Stewart","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref113","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1176\/ajp.144.7.943","article-title":"Absence of carbamazepine-induced hyponatraemia among patients also given lithium","volume":"144","author":"Vieweg","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref101","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1176\/ajp.141.12.1604","article-title":"Lithium-carbamazepine neurotoxicity and risk factors","volume":"141","author":"Shukla","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref099","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5859.135"},{"key":"S0033291700024193_ref107","first-page":"173","article-title":"The use of carbamazepine in the control of manic-depressive psychosis and other states","volume":"13","author":"Takezaki","year":"1971","journal-title":"Clinical Psychiatry"},{"key":"S0033291700024193_ref098","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-85921-2_18"},{"key":"S0033291700024193_ref093","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700053320"},{"key":"S0033291700024193_ref087","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1176\/ajp.143.1.29","article-title":"Anti-depressant effects of carbamazepine","volume":"143","author":"Post","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref095","first-page":"23","article-title":"Carbamazepine and depression","volume":"2","author":"Robertson","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref086","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.04390010083010"},{"key":"S0033291700024193_ref106","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(86)90148-4"},{"key":"S0033291700024193_ref081","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.41.8.713"},{"key":"S0033291700024193_ref078","doi-asserted-by":"publisher","DOI":"10.1007\/BF00428308"},{"key":"S0033291700024193_ref110","first-page":"43","article-title":"Discussion at a meeting on carbamazepine in affective disorders","volume":"2","author":"Trimble","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref077","first-page":"617","article-title":"Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis","volume":"17","author":"Okuma","year":"1975","journal-title":"Seishin-igaku"},{"key":"S0033291700024193_ref075","unstructured":"Okuma T. (1987). Acute and prophylactic properties of carbamazepine in bipolar affective disorders. Presented at a meeting on \u2018New Directions in Affective Disorders\u2019, Jerusalem, Abstract No. S1."},{"key":"S0033291700024193_ref010","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1176\/ajp.140.8.1077","article-title":"Treatment of resistant lithium-induced nephrogenic diabetes insipidus and schizo-affective psychosis with carbamazepine","volume":"140","author":"Brooks","year":"1983","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref071","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90305-1"},{"key":"S0033291700024193_ref069","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04320.x"},{"key":"S0033291700024193_ref068","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb03663.x"},{"key":"S0033291700024193_ref062","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1176\/ajp.139.7.948","article-title":"Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients","volume":"139","author":"Lipinski","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref060","first-page":"309","article-title":"Alternative therapies for bipolar disorder","volume":"46","author":"Lerer","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref057","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1176\/ajp.143.2.235","article-title":"Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal","volume":"143","author":"Klein","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref055","first-page":"88","volume-title":"Anticonvulsants in Affective Disorders","author":"Kishimoto","year":"1984"},{"key":"S0033291700024193_ref046","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1176\/ajp.142.10.1196","article-title":"Haematological effects of carbamazepine in illness","volume":"142","author":"Joffe","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref044","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(87)90061-8"},{"key":"S0033291700024193_ref043","first-page":"122","article-title":"The EEG in obsessive-compulsive disorder","volume":"45","author":"Jenike","year":"1984","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref042","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198504000-00010"},{"key":"S0033291700024193_ref074","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb06735.x"},{"key":"S0033291700024193_ref040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1176\/ajp.136.6.833","article-title":"Organic personality disturbance: a case of apparently atypical cyclic affective disorder","volume":"136","author":"Hellekson","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref039","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410110312"},{"key":"S0033291700024193_ref085","first-page":"51","article-title":"Behavioural pharmacology of carbamazepine: differential effects on kindling","volume":"2","author":"Post","year":"1987","journal-title":"International Clinical Pharmacology"},{"key":"S0033291700024193_ref037","first-page":"423","article-title":"Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient (letter)","volume":"48","author":"Gupta","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref097","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198508000-00009"},{"key":"S0033291700024193_ref080","first-page":"345","article-title":"Carbamazepine in tardive dyskinesia","volume":"21","author":"Per\u00e9nyi","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"key":"S0033291700024193_ref105","first-page":"127","volume-title":"Biological Psychiatry","author":"Stoll","year":"1985"},{"key":"S0033291700024193_ref032","first-page":"236","article-title":"Development of melancholia during carbamazepine treatment in borderline personality disorder","volume":"6","author":"Gardner","year":"1986","journal-title":"Journal of Clinical Pharmacology"},{"key":"S0033291700024193_ref019","doi-asserted-by":"crossref","unstructured":"Elphick M. (1988 a). The clinical uses and pharmacology of carbamazepine in psychiatry. International Clinical Psychopharmacology (in the press).","DOI":"10.1097\/00004850-198807000-00001"},{"key":"S0033291700024193_ref017","first-page":"532","article-title":"Carbamazepine in the treatment of psychiatric and behavioural disorders. A pilot study","volume":"81","author":"De Vogelaer","year":"1981","journal-title":"Acta Psychiatrica Belgica"},{"key":"S0033291700024193_ref016","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1971.tb04380.x"},{"key":"S0033291700024193_ref090","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-197901030-00014"},{"key":"S0033291700024193_ref009","first-page":"73","article-title":"Carbamazepine: pharmacokinetics and interactions","volume":"2","author":"Brodie","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref027","first-page":"416","article-title":"Erythema multiforme major in a patient treated with carbamazepine","volume":"48","author":"Fawcett","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref005","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.137.7.782","article-title":"Carbamazepine (Tegretol) in manic-depressive illness: a new treatment","volume":"137","author":"Ballenger","year":"1980","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref002","first-page":"232","article-title":"Case report of carbamazepine treatment of organic brain syndrome with psychotic features","volume":"6","author":"Anton","year":"1986","journal-title":"Journal of Clinical Pharmacology"},{"key":"S0033291700024193_ref108","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04210080006004"},{"key":"S0033291700024193_ref065","first-page":"37","article-title":"Carbamazepine in the prophylaxis of bipolar affective disorders","volume":"2","author":"Lusznat","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref088","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(87)90045-X"},{"key":"S0033291700024193_ref121","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1176\/ajp.142.6.785b","article-title":"A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder (letter)","volume":"142","author":"Yerevanian","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref066","first-page":"393","article-title":"Carbamazepine in mixed frontal lobe and psychiatric disorders","volume":"46","author":"McAllister","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref056","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790130061009"},{"key":"S0033291700024193_ref076","first-page":"283","article-title":"Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report","volume":"27","author":"Okuma","year":"1973","journal-title":"Folia Psychiatrica et Neurologica Japonica"},{"key":"S0033291700024193_ref022","doi-asserted-by":"publisher","DOI":"10.1007\/BF00589904"},{"key":"S0033291700024193_ref050","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.12.1333"},{"key":"S0033291700024193_ref038","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)92423-0"},{"key":"S0033291700024193_ref102","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(85)90051-5"},{"key":"S0033291700024193_ref030","first-page":"295","volume-title":"Complex Partial Seizures and Their Treatment","volume":"11","author":"Frigerio","year":"1975"},{"key":"S0033291700024193_ref054","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(85)90087-3"},{"key":"S0033291700024193_ref024","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198608000-00007"},{"key":"S0033291700024193_ref048","first-page":"313","article-title":"Effect of carbamazepine on body weight in affectively ill patients","volume":"47","author":"Joffe","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref003","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1176\/ajp.143.5.650","article-title":"Does carbamazepine-induced reduction of haloperidol levels worsen psychotic symptoms?","volume":"143","author":"Arana","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref118","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(88)90011-X"},{"key":"S0033291700024193_ref072","first-page":"160","volume-title":"Anti-convulsants in Affective Disorders","author":"Neumann","year":"1984"},{"key":"S0033291700024193_ref052","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1176\/ajp.141.9.1101","article-title":"Case report of a possible interaction between neuroleptics and carbamazepine","volume":"141","author":"Kanter","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref026","first-page":"58","article-title":"The long-term management of bipolar disorders with lithium, carbamazepine, and anti-depressants","volume":"46","author":"Fawcett","year":"1985","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"S0033291700024193_ref089","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(87)90064-3"},{"key":"S0033291700024193_ref114","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.150.2.180"},{"key":"S0033291700024193_ref115","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1017090"},{"key":"S0033291700024193_ref015","first-page":"11","article-title":"Carbamazepine in acute mania","volume":"2","author":"Cookson","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref006","first-page":"572","article-title":"Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses","volume":"20","author":"Ballenger","year":"1984","journal-title":"Psychopharmacology Bulletin"},{"key":"S0033291700024193_ref013","first-page":"276","article-title":"Carbamazepine and ECT: a paradoxical combination. (Letter.)","volume":"47","author":"Cantor","year":"1986","journal-title":"Journal of Clincial Psychology"},{"key":"S0033291700024193_ref116","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-198707000-00001"},{"key":"S0033291700024193_ref122","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90059-0"},{"key":"S0033291700024193_ref061","first-page":"89","article-title":"Carbamazepine versus lithium in mania: a double-blind study","volume":"48","author":"Lerer","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref053","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1176\/ajp.140.9.1225","article-title":"Carbamazepine in the treatment of bulimia","volume":"140","author":"Kaplan","year":"1983","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref064","first-page":"569","article-title":"Carbamazepine in violent non-epileptic schizophrenics","volume":"20","author":"Luchins","year":"1984","journal-title":"Psychopharmacology Bulletin"},{"key":"S0033291700024193_ref025","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.1.117-a"},{"key":"S0033291700024193_ref023","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(85)90022-9"},{"key":"S0033291700024193_ref051","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1176\/ajp.143.10.1328b","article-title":"Carbamazepine and hyponatraemia (letter)","volume":"143","author":"Juergens","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref091","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1176\/ajp.145.3.361","article-title":"Carbamazepine in the treatment of catatonia","volume":"145","author":"Rankel","year":"1988","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref034","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6222.1122-c"},{"key":"S0033291700024193_ref045","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1985.01790300106015"},{"key":"S0033291700024193_ref001","first-page":"525","article-title":"Lithium and carbamazepine (letter)","volume":"45","author":"Andrus","year":"1984","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref028","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1176\/ajp.139.1.115","article-title":"Carbamazepine treatment of selected affectively disordered inpatients","volume":"139","author":"Folks","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref049","first-page":"87","article-title":"In discussion at a meeting entitled \u2018Carbamazepine in Affective Disorders\u2019","volume":"2","author":"Joyce","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref079","doi-asserted-by":"publisher","DOI":"10.1007\/BF00431111"},{"key":"S0033291700024193_ref036","first-page":"177","volume-title":"Anticonvulsants in Affective Disorders","author":"Grossi","year":"1984"},{"key":"S0033291700024193_ref103","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541931"},{"key":"S0033291700024193_ref067","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90135-8"},{"key":"S0033291700024193_ref059","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.2.265-b"},{"key":"S0033291700024193_ref109","first-page":"1","article-title":"Antiepileptic and psychotropic properties of carbamazepine","volume":"2","author":"Trimble","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"key":"S0033291700024193_ref031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1176\/ajp.143.4.519","article-title":"Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder","volume":"143","author":"Gardner","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref096","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1984.tb02508.x"},{"key":"S0033291700024193_ref041","first-page":"465","article-title":"A lithium and carbamazepine combination in the treatment of bipolar disorder \u2013 a preliminary report","volume":"35","author":"Inoue","year":"1981","journal-title":"Folia Psychiatrica et Neurologica Japonica"},{"key":"S0033291700024193_ref004","first-page":"159","article-title":"Therapeutic effects of carbamazepine in affective illness: a preliminary report","volume":"2","author":"Ballenger","year":"1978","journal-title":"Communications in Psychopharmacology"},{"key":"S0033291700024193_ref021","doi-asserted-by":"publisher","DOI":"10.1177\/026988118800200101"},{"key":"S0033291700024193_ref100","unstructured":"Sillanpaa M. (1981). Carbamazepine. Pharmacology and clinical uses. Acta Neurologica Scandinavica. Suppl. 88."},{"key":"S0033291700024193_ref070","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(85)90077-1"},{"key":"S0033291700024193_ref007","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.144.3.317"},{"key":"S0033291700024193_ref011","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1176\/ajp.143.11.1487a","article-title":"Combined carbamazepine and lithium therapy for violent behaviour. (Letter.)","volume":"143","author":"Buck","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref033","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.V61.5.889.889","article-title":"Anti-convulsant-induced aplastic anaemia: increased susceptibility to toxic drug metabolites in vitro","volume":"61","author":"Gerson","year":"1983","journal-title":"Blood"},{"volume-title":"Martindale: The Extra Pharmacopoeia.","year":"1982","author":"Reynolds","key":"S0033291700024193_ref094"},{"key":"S0033291700024193_ref008","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1976.tb00081.x"},{"key":"S0033291700024193_ref058","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/clpt.1985.115","article-title":"Hyponatraemia during carbamazepine therapy","volume":"37","author":"Laker","year":"1985","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"S0033291700024193_ref012","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1979.tb04142.x"},{"key":"S0033291700024193_ref020","doi-asserted-by":"crossref","unstructured":"Elphick M. (1988 b). The effects of carbamazepine on dopamine function in rodents. Psychopharmacology (in the press).","DOI":"10.1007\/BF00589904"},{"key":"S0033291700024193_ref063","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(86)72590-5"},{"key":"S0033291700024193_ref029","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(88)90194-0"},{"key":"S0033291700024193_ref092","first-page":"338","article-title":"Successful treatment course with carbamazepine despite initial significant leukopoenia: case report","volume":"48","author":"Regan","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0033291700024193_ref035","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1176\/ajp.143.11.1486","article-title":"Sedative or anti-manic effects of carbamazepine and treatment of behavioural dyscontrol (letter)","volume":"143","author":"Greenberg","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref083","first-page":"131","article-title":"Carbamazepine for treatment resistant depressions?","volume":"143","author":"Post","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"S0033291700024193_ref073","first-page":"139","article-title":"Carbamazepine levels in pregnancy and lactation","volume":"53","author":"Nidely","year":"1979","journal-title":"Obstetrics and Gynaecology"},{"key":"S0033291700024193_ref112","first-page":"103","article-title":"Effect of carbamazepine on serum electrolytes: clinical and theoretical implications","volume":"3","author":"Uhde","year":"1983","journal-title":"Journal of Clinical Psychopharmacology and Therapy"},{"key":"S0033291700024193_ref018","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.147.2.198"},{"key":"S0033291700024193_ref047","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700009144"}],"container-title":["Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0033291700024193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T21:05:56Z","timestamp":1739221556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0033291700024193\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,8]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1989,8]]}},"alternative-id":["S0033291700024193"],"URL":"https:\/\/doi.org\/10.1017\/s0033291700024193","relation":{},"ISSN":["0033-2917","1469-8978"],"issn-type":[{"type":"print","value":"0033-2917"},{"type":"electronic","value":"1469-8978"}],"subject":[],"published":{"date-parts":[[1989,8]]}}}